Silver Book Fact

Fact image

2006 Medicines in Development for Neurologic Disorders

2006 Report: Medicines in development for neurological disorders. http://www.phrma.org/files/Neurologic_2006.pdf. Published 2006

Reference

Title
2006 Report: Medicines in development for neurological disorders
Publisher
PhRMA
Publication Date
Published 2006
Authors
PhRMA
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Delaying the onset and progression of Alzheimer’s disease would reduce the projected number of people with moderate to severe cases of the disase to 4.4 million instead of 10.3 million…  
  • Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.  
  • In one study, deep-brain stimulation for Parkinson’s patients significantly reduced their required dosages of antiparkinsonian medications, consequently decreasing their medication costs by 32% 1 year after surgery, and 39% 2…  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the Medicare costs for people with the disease in 2050 by…  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the total costs of care for people with the disease by…